We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

165 hedge funds and large institutions have $824M invested in Aimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 72 increasing their positions, 37 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 37

69% more call options, than puts

Call options by funds: $8.66M | Put options by funds: $5.11M

18% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 22

16% more capital invested

Capital invested by funds: $712M → $824M (+$113M)

2% more funds holding

Funds holding: 161 → 165 (+4)

Holders
165
Holders Change
+4
Holders Change %
+2.48%
% of All Funds
3.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
72
Reduced
37
Closed
22
Calls
$8.66M
Puts
$5.11M
Net Calls
+$3.55M
Net Calls Change
+$2.3M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$25.9M
2
First Manhattan
First Manhattan
New York
+$17.4M
3
AC
Armistice Capital
New York
+$5.5M
4
SCA
Southpoint Capital Advisors
New York
+$5.09M
5
BlackRock
BlackRock
New York
+$5.03M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$28.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$13.1M
3
Morgan Stanley
Morgan Stanley
New York
-$11.3M
4
EAM
Eventide Asset Management
Massachusetts
-$11.2M
5
NCM
Nantahala Capital Management
Connecticut
-$8.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAPTRUST Financial Advisors
151
CAPTRUST Financial Advisors
North Carolina
$4K +$4.5K +265 New
LC
152
Lindbrook Capital
California
$3K -$2.75K -162 -51%
JCM
153
Jacobi Capital Management
Pennsylvania
$3K – – –
SSB
154
Sandy Spring Bank
Maryland
$3K +$951 +56 +60%
APWA
155
Atlas Private Wealth Advisors
New Jersey
$3K +$3.4K +200 New
Lazard Asset Management
156
Lazard Asset Management
New York
$3K +$3.43K +202 New
SF
157
Synovus Financial
Georgia
$2K -$13.6K -800 -85%
CFGS
158
Concourse Financial Group Securities
Alabama
$2K – – –
DI
159
Disciplined Investments
Oklahoma
$2K – – –
BWM
160
BerganKDV Wealth Management
Minnesota
$1K – – –
HWM
161
HighMark Wealth Management
Minnesota
$1K – – –
IRC
162
Investors Research Corp
Georgia
$1K – – –
AssetMark Inc
163
AssetMark Inc
California
$1K +$238 +14 +19%
CFD
164
Creative Financial Designs
Indiana
$1K +$1.27K +75 New
APM
165
Avidity Partners Management
Texas
– -$5.88M -408,000 Closed
Renaissance Technologies
166
Renaissance Technologies
New York
– -$1.57M -108,900 Closed
State of New Jersey Common Pension Fund D
167
State of New Jersey Common Pension Fund D
New Jersey
– -$1.15M -79,704 Closed
Neuberger Berman Group
168
Neuberger Berman Group
New York
– -$613K -42,525 Closed
SEC
169
Seven Eight Capital
New York
– -$421K -29,200 Closed
FC
170
FORA Capital
Florida
– -$275K -19,094 Closed
SIM
171
Spark Investment Management
New York
– -$262K -18,200 Closed
Wolverine Trading
172
Wolverine Trading
Illinois
– -$281K -16,525 Closed
AI
173
Atria Investments
North Carolina
– -$234K -16,237 Closed
NIT
174
NumerixS Investment Technologies
British Columbia, Canada
– -$212K -14,698 Closed
TI
175
Trexquant Investment
Connecticut
– -$201K -13,953 Closed
4 5 6
7
8

AIMT Hedge Fund Activity: Q2 2020 in Review

165 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2020, worth a combined $824M — up 16% from $712M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AIMT positions and 22 closed out — a net gain of 4 holders — while 72 added to existing stakes and 37 trimmed.

The largest buyer was State Street, adding an estimated $25.9M. The largest seller was Victory Capital Management, cutting an estimated $28.9M.

  • 165 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2020, up from 161 in Q1 2020.
  • Funds reported $824M of Aimmune Therapeutics stock for Q2 2020, up 16% quarter-over-quarter.
  • 26 funds opened new Aimmune Therapeutics positions in Q2 2020 and 22 closed out, a net change of +4 holders.
  • The largest Aimmune Therapeutics buyer in Q2 2020 was State Street, an estimated $25.9M added.
  • The largest Aimmune Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $28.9M sold.

Based on aggregated 13F filings for Q2 2020.